07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Aridol mannitol Bronchial Challenge Test Kit regulatory update

Pharmaxis said FDA placed its Aridol mannitol Bronchial Challenge Test Kit to assess bronchial hyperresponsiveness in patients >=6 years of age who do not have clinically apparent asthma on an import alert list, which prevents...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

Aridol mannitol Bronchial Challenge Test Kit regulatory update

Pharmaxis said the Centers for Medicare & Medicaid Services (CMS) assigned a J-code for reimbursement of its Aridol mannitol Bronchial Challenge Test Kit to assess bronchial hyperresponsiveness in patients >=6 years of age who do...
07:00 , May 5, 2011 |  BC Innovations  |  Cover Story

LIGHTs out for asthma

Two years after Kyowa Hakko Kirin Co. Ltd.granted sanofi-aventis Groupan exclusive license to an antibody against the tumor necrosis factor ligand LIGHT to treat irritable bowel disease, researchers at the La Jolla Institute for Allergy...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

Pharmaxis sales and marketing update

Pharmaxis launched its Aridol mannitol Bronchial Challenge Test Kit in the U.S. to assess bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma. The indirect bronchial...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the optimism is...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Trickle-down effect

Although companies in the $1-$1.9 billion market cap range were the big winners for 2010 with a 28% gain, last quarter saw gains migrate into lower rungs of the market cap ladder. Small caps with $200-$499...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Aridol Bronchial Challenge Test Kit regulatory update

FDA approved an NDA from Pharmaxis for its Aridol Bronchial Challenge Test Kit to assess bronchial hyperresponsiveness in patients 6 years of age and older who do not have clinically apparent asthma. The company plans...
07:00 , Oct 11, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Human Genome Sciences Inc. (NASDAQ:HGSI) was off $0.16 to $29.15 last week when it said it would discontinue development of Zalbin albinterferon alfa-2b after FDA issued a complete response letter for a BLA for...
23:41 , Oct 6, 2010 |  BC Extra  |  Company News

FDA approves Pharmaxis' Aridol

FDA approved an NDA from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) for Aridol Bronchial Challenge Test Kit to assess bronchial hyperresponsiveness in patients six or older who do not have clinically apparent asthma. The company plans to...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Aridol mannitol regulatory update

FDA accepted for review an NDA resubmission from Pharmaxis for Aridol mannitol powder inhalation test to assess bronchial hyperresponsiveness as an aid in the diagnosis of patients six years of age and older with symptoms...